Memorial Sloan Kettering physician-scientist David Scheinberg

David A. Scheinberg, MD, PhD

Leukemia Specialist & Physician-Scientist

Areas of Expertise

Conditions I Treat

  • Leukemia
  • Acute lymphocytic leukemia (ALL)
  • Acute myeloid leukemia (AML)

My Specialties

  • Immunotherapy
  • Cancer vaccines
  • Clinical trials
View more expertise
Dr. Scheinberg's Office Information
Languages: English

Get to Know Me

Dr. Scheinberg is a physician-scientist who specializes in the care of patients with leukemia and is also investigating new therapeutic approaches to cancer, both in the clinic and in the laboratory. His research is focused on discovering and developing novel, specific immunotherapeutic agents. These include monoclonal antibodies that target the cell surface of cancers, intracellular proteins, engineered cells, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, targeted nanodevices that selectively kill cancer cells, and therapeutic vaccines that target the oncogene products that cause the cancers.

Eight different therapeutic agents developed by Dr. Scheinberg in his laboratory have reached human clinical trials, including the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg has published more than 350 papers, chapters, and books in these fields.

Dr. Scheinberg currently holds the Vincent Astor Chair at Memorial Sloan Kettering Cancer Center (MSK) and is a member of the Molecular Pharmacology Program in the Sloan Kettering Institute (SKI), where he also serves as Deputy Director for Therapeutic Disovery. Additionally, Dr. Scheinberg  founded and chairs the Experimental Therapeutics and formerly the Nanotechnology Center at MSK. He is a professor of medicine and pharmacology and co-chair of the pharmacology graduate program at Weill-Cornell Medical College and a professor at the Gerstner Sloan Kettering Graduate School. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Cornell, and Rockefeller Universities. 

From 1992 until 2002, Dr. Scheinberg was Chief of the Leukemia Service in Memorial Hospital and served as Chairman of Molecular Pharmacology from 2001 through 2022. He has been elected into the American Society of Clinical Investigation, the American Association of Physicians, and the Interurban Club. His other awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, the Leukemia and Lymphoma Society Translational Investigator Awards, and CapCure Awards. He is an advisor to charitable foundations, cancer centers, and biotech companies.

What I Do at MSK

I’m a leukemia specialist, which is a doctor with special training in diagnosing and treating leukemia (loo-KEE-mee-uh). This cancer starts in tissue that forms blood, such as bone marrow.

I'm a physician-scientist, which is a doctor who also is a researcher.

  • Chairman, Experimental Therapeutics Center
  • Vincent Astor Chair
  • Deputy Director, Therapeutic Discovery, Sloan Kettering Institute
Areas of Expertise

Conditions I Treat

  • Leukemia
  • Acute lymphocytic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Acute promyelocytic leukemia (APL)
  • Chronic lymphocytic leukemia (CLL)
  • Chronic myeloid leukemia (CML)
  • Myeloproliferative neoplasms (MPN)/Myeloproliferative disorders
  • Hairy cell leukemia (HCL)
  • Systemic mastocytosis
  • Blood, bone marrow, and hematologic cancers and conditions

My Specialties

  • Immunotherapy
  • Cancer vaccines
  • Clinical trials
  • Drug development
Education & Honors

Education

  • MD, PhD, The Johns Hopkins School of Medicine

Residencies

  • The New York Hospital/Cornell Medical Center

Fellowships

  • Memorial Sloan Kettering Cancer Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Contact and Location

Office Phone
Location
New York, NY
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
530 East 74th Street New York NY 10021
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Leukemia Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. Scheinberg's Lab

Publications on PubMed

Visit PubMed for a full listing of Dr. Scheinberg’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

David A. Scheinberg discloses the following relationships and financial interests:

  • Actinium
    Equity; Intellectual Property Rights; Professional Services and Activities (Uncompensated)
  • Arvinas, Inc.
    Equity
  • Atengen, Inc.
    Equity; Professional Services and Activities (Uncompensated)
  • Century Therapeutics
    Intellectual Property Rights
  • Epics Therapeutics S.A.
    Professional Services and Activities
  • Estrella Biopharma, Inc.
    Professional Services and Activities
  • Eureka Therapeutics Inc
    Equity; Professional Services and Activities (Uncompensated)
  • Great Point Partners
    Equity; Professional Services and Activities
  • Iovance Biotherapeutics, Inc.
    Equity
  • Lantheus Medical Imaging, Inc.
    Equity
  • Lilly Oncology
    Equity
  • Omnipotent Bio Holdings, Inc.
    Equity; Professional Services and Activities
  • Pfizer, Inc.
    Equity
  • Repertoire Immune Medicines, Inc.
    Professional Services and Activities
  • Sapience Therapeutics, Inc.
    Equity; Fiduciary Role / Position
  • Sellas Life Science Group
    Equity; Fiduciary Role / Position; Intellectual Property Rights

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: